Trial Number
381-23
Condition
Lymphoma
Participant Age Range
5 years to 60 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma”
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab.